Insurers, pharmacy-benefit managers, Medicaid programs and employers are changing GLP-1 weight-loss coverage every month. Each entry below quotes the policy or report itself, says what remains covered, and lays out the published cash-pay routes, including ours.
By Dr. SkinnyVIP · Published October 19, 2026 · Quotes link to the original policy or report
1. Ask your plan one question in writing. “Is there a continuation-of-therapy or medical-necessity exception for members already on a GLP-1, and what documentation does it need?” Many policies keep an exception for diabetes, cardiovascular risk reduction, sleep apnea or liver disease; a letter from your prescriber may qualify you.
2. Check the two public cash-pay routes for the brand-name drug. LillyDirect sells Zepbound to self-pay patients at published prices by dose ($299 to $699 a month for vials as of October 2026, per our Real-Price Index). If you are on Medicare Part D, the Medicare GLP-1 Bridge offers Wegovy or Zepbound for a $50 copay through December 2027 if you meet its criteria (details).
3. If neither fits, know the compounded option's real number. SkinnyVIP's clinician-prescribed compounded tirzepatide is $695 for a 3-month plan (about $232 a month) or $350 for a single month, the same price at every dose, with no membership, no subscription and no automatic renewal; you pay once per plan and nothing bills again unless you ask. If a licensed clinician does not prescribe, the medication cost is refunded in full. Compounded medications are not FDA-approved products; read how it works and what that means before deciding.
SkinnyVIP sells clinician-prescribed compounded tirzepatide at $695 for a 3-month plan (about $232 a month) or $350 for a single month, the same price at every dose from 2.5 mg to 15 mg. There is no subscription, no membership fee, no auto-renewal and no stored card; a refill happens only when the patient asks for one. If a licensed clinician does not prescribe, the medication cost is refunded in full. A person, never a bot, answers messages within one hour, 7 days a week, 9am to 9pm ET, in English or Spanish. Compounded medications are not FDA-approved products.
Cost. Business Group on Health's 2027 survey, reported by SHRM, put pharmacy at 25% of employers' healthcare spend, with drug costs rising an estimated 12% in 2026; Medicaid programs in several states cited the same strain. Coverage for type 2 diabetes is generally continuing; weight-loss-only coverage is what is being removed.
Not necessarily. Ask your plan about continuation-of-therapy or medical-necessity exceptions, check whether you qualify under another covered indication (diabetes, cardiovascular risk, sleep apnea, liver disease), check the Medicare GLP-1 Bridge if you are on Part D, and compare the published cash-pay prices for brand-name and compounded options.
Whenever a coverage change is published by an insurer, PBM, Medicaid program or a major employer, we add a dated entry quoting the source. Entries are never edited to change what a policy said; corrections are added as dated notes.
No. Zepbound is the FDA-approved tirzepatide product made by Eli Lilly. Compounded tirzepatide is prepared by licensed compounding pharmacies under physician supervision for an individual patient; it is not FDA-approved, and FDA does not review compounded drugs for safety, effectiveness or quality before marketing.
$695 for a 3-month plan (about $232/month) or $350 for one month, any dose. You only pay if a licensed clinician approves treatment.
Start your consultationCompounded tirzepatide is prepared by licensed compounding pharmacies under physician supervision. Compounded medications are not FDA-approved products, and FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Compounded tirzepatide is separate from FDA-approved Mounjaro® and Zepbound®. A licensed clinician reviews every request; prescription is not guaranteed. Individual results vary. Not affiliated with Novo Nordisk (Ozempic®/Wegovy®) or Eli Lilly (Mounjaro®/Zepbound®). This page is general information about published coverage policies, not insurance, legal or medical advice; confirm details with your plan.